Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other major diseases. Its lead investigational product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to penetrate solid tumors. LSTA1 actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs penetrating and accumulating in the tumor, while normal tissues are not affected. LSTA1 also has the potential to modify the tumor microenvironment (TME). It is exploring the potential of LSTA1 to enable a variety of treatment modalities to treat a range of solid tumors. Its CD34+ is a cell therapy technology was targeting an array of diseases, among them, critical limb ischemia, coronary microvascular dysfunction, and diabetic kidney disease.

• Revenue in USD (TTM)0.00
• Net income in USD-20.05m
• Incorporated1980
• Employees25.00

• Location
  Lisata Therapeutics Inc110 Allen Road, Second FloorBASKING RIDGE 07920United StatesUSA
• Phone+1 (908) 229-2590
• Fax+1 (845) 818-3588
• Websitehttps://www.lisata.com/